USAN Watch - February 2012
| USAN | Research Code | Structure | Drug Class | Therapeutic class | Target |
| aladorian, aladorian sodium | S44121-1, ARM-036, S36 |  | synthetic small molecule | therapeutic | RyR |
| avatrombopag, avatrombopag maleate | E-5501, AKR-501 |  | synthetic small molecule | therapeutic | TPOR |
| balugrastim | CG-10639 | protein | therapeutic | GCSFR | |
| baricitinib | LY-3009104, INCB-028050 |  | synthetic small molecule | therapeutic | JAK1 JAK2 |
| blisibimod | A-623 | protein | therapeutic | BAFF-R | |
| brexipiprazole | OPC-34712 |  | synthetic small molecule | therapeutic | D2R |
| clazakizumab | BMS-945429, ALD-518 | mab | therapeutic | IL-6 | |
| enobosarm | GTx-024 |  | synthetic small molecule | therapeutic | AR |
| ertugliflozin | PF-04971729-00 |  | synthetic small molecule | therapeutic | SGLT2 |
| firtecan pegol | EZN-2208 |  | synthetic small molecule conjugate prodrug | therapeutic | topo 1 |
| giminabant |  | synthetic small molecule | therapeutic | CB2 | |
| ibrutinib | PCI-32765, CRA-032765, PCI-32765-00 |  | synthetic small molecule | therapeutic | BTK |
| lipefilgrastim | XM-22 | protein | therapeutic | GCSFR | |
| momelotinib | CYT-387 |  | synthetic small molecule | therapeutic | JAK1 JAK2 |
| omarigliptin | MK-3102 (?) |  | synthetic small molecule | therapeutic | DPP-IV |
| oprozomib | ONX-0912 |  | synthetic small molecule | therapeutic | proteasome |
| nivolumab | MDX-1106, BMS-936558 | mab | therapeutic | DR1 | |
| placulumab | CEP-37247, ART-621, PN-0621 | mab | therapeutic | TNFa | |
| quisinostat | JNJ-26481585 |  | synthetic small molecule | therapeutic | HDAC |
| saridegib, saridegib hydrochloride | IPI-926, FIN-5 |  | natural product-derived small molecule | therapeutic | smoothened |
| technetium Tc 99m etarfolatide | EC-20 |  | synthetic small molecule | imaging agent | Folate receptor |
| vocimagene amiretrorepvec | TOCA-511 | viral vector | therapeutic |
If anyone can confirm the MK- number for omarigliptin, or knows the MK- number for giminabant that would be great, as would the sequences for clazakizumab, nivolumab, placulumab.